Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies

Abstract

SummaryBackgroundPersistent inflammation has been proposed to contribute to various stages in the pathogenesis of cardiovascular disease. Interleukin-6 receptor (IL6R) signalling propagates downstream inflammation cascades. To assess whether this pathway is causally relevant to coronary heart disease, we studied a functional genetic variant known to affect IL6R signalling.MethodsIn a collaborative meta-analysis, we studied Asp358Ala (rs2228145) in IL6R in relation to a panel of conventional risk factors and inflammation biomarkers in 125 222 participants. We also compared the frequency of Asp358Ala in 51 441 patients with coronary heart disease and in 136 226 controls. To gain insight into possible mechanisms, we assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.FindingsThe minor allele frequency of Asp358Ala was 39%. Asp358Ala was not associated with lipid concentrations, blood pressure, adiposity, dysglycaemia, or smoking (p value for association per minor allele ≥0·04 for each). By contrast, for every copy of 358Ala inherited, mean concentration of IL6R increased by 34·3% (95% CI 30·4–38·2) and of interleukin 6 by 14·6% (10·7–18·4), and mean concentration of C-reactive protein was reduced by 7·5% (5·9–9·1) and of fibrinogen by 1·0% (0·7–1·3). For every copy of 358Ala inherited, risk of coronary heart disease was reduced by 3·4% (1·8–5·0). Asp358Ala was not related to IL6R mRNA levels or interleukin-6 production in monocytes.InterpretationLarge-scale human genetic and biomarker data are consistent with a causal association between IL6R-related pathways and coronary heart disease.FundingBritish Heart Foundation; UK Medical Research Council; UK National Institute of Health Research, Cambridge Biomedical Research Centre; BUPA Foundation.

C‐Reactive Protein Identifies Low‐Risk Metabolically Healthy Obese Persons: The European Prospective Investigation of Cancer–Norfolk Prospective Population Study

“…Similarly, Gupta et al reported that the association between CRP and atherosclerosis is diminished in obese persons aged 30 to 65 years 35. The role of interleukin 6 was recently corroborated by 3 mendelian‐based association studies 36, 37, 38. Single‐nucleotide polymorphisms associated with decreased interleukin 6 signaling were found to correlate with lower values of acute‐phase reactants, such as CRP and fibrinogen, with a concomitant proportional reduction in cardiovascular risk.…”

Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty

“…By contrast, IL-6 and IL-1 contribute to atherosclerosis and should be considered to be therapeutic targets 158,163 . Mendelian randomization studies have shown that polymorphisms that affect IL-6 signalling are associated with lower life-time risk of cardiovascular disease 23,24 . In the MEASURE trial 165 , the IL-6 receptor blocker tocilizumab increased the concentration of HDL particles in patients with rheumatoid arthritis compared with placebo, despite an increase multicentre ENTRACTE trial 166 compared the cardiovascular safety profile of tocilizumab to that of the TNF inhibitor etanercept in >3,000 patients with moderate-to-severe rheumatoid arthritis, but the final results are not yet published.…”

Ten‐year alcohol consumption typologies and trajectories of C‐reactive protein, interleukin‐6 and interleukin‐1 receptor antagonist over the following 12 years: a prospective cohort study

“…For example, higher levels of the acute‐phase reactant C‐reactive protein (CRP) are associated with an increased risk of developing CVD 16 and a variety of other disease end‐points 17. Studies have demonstrated that higher levels of interleukin (IL)‐6 are associated with an increased risk of coronary heart disease (CHD) 18, including studies examining long‐term exposure to elevated IL‐6 19 or functional genetic variants of IL‐6 signalling 20, suggesting that the association is causal. IL‐1 is considered a master regulator of inflammation that triggers the release of a variety of inflammatory markers through activating the IL‐1 receptor.…”